DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations

DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations

Background: Breast cancers can be divided into HER2-negative and HER2-positive subtypes according to different status of HER2 gene. Despite extensive studies connecting germline mutations with possible risk of HER2-negative breast cancer, the main category of breast cancer, it remains challenging to...

Full description

Bibliographic Details
Main Authors:	Mei Yang, Yanhui Fan, Zhi-Yong Wu, Jin Gu, Zhendong Feng, Qiangzu Zhang, Shunhua Han, Zhonghai Zhang, Xu Li, Yi-Ching Hsueh, Yanxiang Ni, Xiaoling Li, Jieqing Li, Meixia Hu, Weiping Li, Hongfei Gao, Ciqiu Yang, Chunming Zhang, Liulu Zhang, Teng Zhu, Minyi Cheng, Fei Ji, Juntao Xu, Hening Cui, Guangming Tan, Michael Q. Zhang, Changhong Liang, Zaiyi Liu, You-Qiang Song, Gang Niu, Kun Wang
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	EBioMedicine
Subjects:	HER2-negative breast cancer Germline rare coding mutations Damage assessment of genomic mutations (DAGM) Risk assessment Activity profiles of signalling pathways (APSP) HER2 signalling pathway
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396421002395

Similar Items

The potential of panHER inhibition in cancer
by: Xiaochun eWang, et al.
Published: (2015-01-01)

Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
by: Raghuveer Kavarthapu, et al.
Published: (2021-09-01)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
by: Li, M., et al.
Published: (2022)

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
by: M. Janusz Mezynski, et al.
Published: (2021-05-01)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
by: Yan Wang, et al.
Published: (2018-03-01)

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
by: Sinead Toomey, et al.
Published: (2017-07-01)

Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review
by: Qu Y, et al.
Published: (2021-03-01)

The role of collagen in cancer: from bench to bedside
by: Shuaishuai Xu, et al.
Published: (2019-09-01)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
by: Yalikong A, et al.
Published: (2021-03-01)

Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
by: Reyhaneh Farghadani, et al.
Published: (2021-07-01)

Targeting HER2 expression in cancer: New drugs and new indications
by: Semir Vranic, et al.
Published: (2020-06-01)

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab
by: Zhang Y, et al.
Published: (2019-12-01)

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
by: Hu H, et al.
Published: (2020-05-01)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
by: Qitong Chen, et al.
Published: (2020-05-01)

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
by: Qitong Chen, et al.
Published: (2021-03-01)

Pharmacological Characteristics of Porcine Orexin 2 Receptor and Mutants
by: Min Liu, et al.
Published: (2020-03-01)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
by: Xu J, et al.
Published: (2018-04-01)

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
by: Alexey Goltsov, et al.
Published: (2014-06-01)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
by: Jung Won Shin, et al.
Published: (2019-10-01)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
by: Lei L, et al.
Published: (2019-04-01)

HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway
by: Chi F, et al.
Published: (2016-05-01)

Noonan syndrome – a new survey
by: Alireza Tafazoli, et al.
Published: (2016-12-01)

Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives
by: Michela Croce, et al.
Published: (2019-06-01)

Alterations of Signaling Pathways in Essential Thrombocythemia with Calreticulin Mutation
by: Hui W, et al.
Published: (2021-08-01)

Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report
by: Shan J, et al.
Published: (2020-10-01)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
by: Andreia Gameiro, et al.
Published: (2021-03-01)

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
by: Wu Xianhua, et al.
Published: (2012-08-01)

Rasopathies case report: concurrence of two pathogenic variations de novo in NF1 and KRAS genes in a patient
by: Irene Baquedano Lobera, et al.
Published: (2019-04-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Radiosensitisation of low HER-2 expressing human breast cancer cell lines
by: Hamid, Mogammad Baahith
Published: (2015)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
by: Sasagu Kurozumi, et al.
Published: (2020-08-01)

Pattern of recurrence and survival in TNBC-a retrospective study done in a rural based medical college and hospital of West Bengal India
by: Acharya, S., et al.
Published: (2021)

Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma
by: Hamid Maadi, et al.
Published: (2021-07-01)

Progress in the genetics research of infantile hemangioma and vascular malformations
by: ZHENG Jiawei, et al.
Published: (2019-12-01)

Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors
by: Lianbao Ye, et al.
Published: (2019-01-01)

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis
by: Zhou C, et al.
Published: (2018-09-01)

Recent advances in signaling pathways related to choroidal neovascularization
by: Bao-Di Deng, et al.
Published: (2019-05-01)

Identification of Common Driver Gene Modules and Associations between Cancers through Integrated Network Analysis
by: Bo Gao, et al.
Published: (2021-09-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)